These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1064 related items for PubMed ID: 19553630

  • 1. Herpes zoster pathogenesis and cell-mediated immunity and immunosenescence.
    Oxman MN.
    J Am Osteopath Assoc; 2009 Jun; 109(6 Suppl 2):S13-7. PubMed ID: 19553630
    [Abstract] [Full Text] [Related]

  • 2. [Reactivation of herpes zoster infection by varicella-zoster virus].
    Cvjetković D, Jovanović J, Hrnjaković-Cvjetković I, Brkić S, Bogdanović M.
    Med Pregl; 1999 Jun; 52(3-5):125-8. PubMed ID: 10518396
    [Abstract] [Full Text] [Related]

  • 3. A novel vaccine (Zostavax) to prevent herpes zoster and postherpetic neuralgia.
    Holcomb K, Weinberg JM.
    J Drugs Dermatol; 2006 Oct; 5(9):863-6. PubMed ID: 17039651
    [Abstract] [Full Text] [Related]

  • 4. Prevention strategies: herpes zoster, post-herpetic neuralgia and immunogenicity.
    Levin MJ, Schmader K.
    Herpes; 2007 Sep; 14 Suppl 2():45-7. PubMed ID: 17939896
    [Abstract] [Full Text] [Related]

  • 5. [Herpes zoster and postherpetic neuralgia - prevention by vaccination?].
    Wutzler P.
    Dtsch Med Wochenschr; 2009 Apr; 134 Suppl 2():S90-4. PubMed ID: 19353479
    [Abstract] [Full Text] [Related]

  • 6. Vaccination: a new option to reduce the burden of herpes zoster.
    Mick G.
    Expert Rev Vaccines; 2010 Mar; 9(3 Suppl):31-5. PubMed ID: 20192716
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Prevention of shingles by varicella zoster virus vaccination.
    Holodniy M.
    Expert Rev Vaccines; 2006 Aug; 5(4):431-43. PubMed ID: 16989624
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Herpes zoster ophthalmicus natural history, risk factors, clinical presentation, and morbidity.
    Liesegang TJ.
    Ophthalmology; 2008 Feb; 115(2 Suppl):S3-12. PubMed ID: 18243930
    [Abstract] [Full Text] [Related]

  • 16. [Herpes zoster and post-herpetic neuralgia in older adults].
    Lang PO, Zarate-Lagunes M, Pautex S.
    Rev Med Suisse; 2008 Nov 05; 4(178):2398-402, 2404. PubMed ID: 19051627
    [Abstract] [Full Text] [Related]

  • 17. Herpes zoster overview: natural history and incidence.
    Weaver BA.
    J Am Osteopath Assoc; 2009 Jun 05; 109(6 Suppl 2):S2-6. PubMed ID: 19553632
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Safety and tolerability of a high-potency zoster vaccine in adults >/= 50 or years of age.
    Tyring SK, Diaz-Mitoma F, Padget LG, Nunez M, Poland G, Cassidy WM, Bundick ND, Li J, Chan IS, Stek JE, Annunziato PW, Protocol 009 Study Group.
    Vaccine; 2007 Feb 26; 25(10):1877-83. PubMed ID: 17227688
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 54.